Abstract
Background
Recent evidence has emerged that a dopamine agonist, pramipexole, may increase the risk of heart failure among Caucasian patients, but the association has not been examined among Asian patients. The aim of this study was to explore the relationship between use of dopamine agonists and the risk of heart failure.
Methods
Using data from Taiwan’s National Health Insurance research database (NHIRD), we identified a population-based cohort comprising 27,135 patients who were prescribed anti-parkinsonian drugs between 2001 and 2010. We conducted a nested case–control study in which 1,707 cases of newly diagnosed heart failure were matched to 3,414 controls (1:2 matched according to age, gender and cohort entry year) within this cohort. Multivariable conditional logistic regressions were used to estimate the association between use of dopamine agonists and heart failure.
Results
An increased risk of heart failure was observed with current use of ergot-derived dopamine agonists (adjusted odds ratio [OR] 1.46, 95 % confidence interval [CI] 1.00–2.12) but not with current use of non-ergot-derived dopamine agonists (adjusted OR 1.24, 95 % CI 0.84–1.82). Among non-ergot-derived dopamine agonists, both pramipexole (adjusted OR 1.40, 95 % CI 0.75–2.61) and ropinirole (adjusted OR 1.22, 95 % CI 0.76–1.95) showed a non-significantly increased heart failure risk. Although the findings of our study were limited by lack of statistical power, a clear pattern of an increased duration of pramipexole use and an increased risk of heart failure were observed.
Conclusion
Use of dopamine agonists, including pramipexole, was associated with non-significantly increased risks of heart failure in this population-based study in Taiwan. Further investigation is needed to clarify this potential association.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68(6):685–9.
US Food and Drug Administration. FDA drug safety communication: ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure. http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm#data. Accessed 16 Jan 2013.
Renoux C, Dell’Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21(1):34–41.
Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65(3):358–64.
Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan’s national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15(2):99–108.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38.
Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case–control study. Drug Saf. 2012;35(2):159–71.
Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med. 2005;353(18):1976–7.
Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003;61(6):859–61.
Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57(5):729–32.
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–53.
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236–42.
Hsiao FY, Tsai YW, Wen YW, Chen PF, Chou HY, Chen CH, et al. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010;19(8):786–91.
Acknowledgments
We thank the Bureau of National Health Insurance (BNHI) and National Health Research Institutes (NHRI) for making available the databases used in this study. However, the content of this article in no way represents any official position of the BNHI or NHRI. The authors bear all responsibilities for the study results and the interpretation of the results. The study was supported by a research grant (no. DOH101-FDA-41100) sponsored by the Food and Drug Administration, Taiwan. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author contributions
Dr. F. Y. Hsiao and Ms. P. H. Hsieh were responsible for development of the study concept and design, and for the preparation of the manuscript. Ms. P. H. Hsieh contributed to the data acquisition and statistical analysis. Both authors participated in the analysis and interpretation of the data, read and approved the manuscript for submission.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hsieh, P.H., Hsiao, F.Y. Risk of Heart Failure Associated with Dopamine Agonists: A Nested Case–Control Study. Drugs Aging 30, 739–745 (2013). https://doi.org/10.1007/s40266-013-0102-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-013-0102-z